Sanuwave Q2 revenue $9.7M (-3% YoY), net loss $0.7M; withdraws FY2026 guidance on CMS reimbursement uncertainty

SANUWAVE Health, Inc.

2026-Q2 EPS reported -$0.25 revenue$19,358,000

Revenue $9.7M, down 3% from $10.1M in Q2 2025; gross margin 76.2% vs 78.1%.
GAAP operating loss $(0.3)M vs income $1.4M; net loss $0.7M vs net income $0.6M.
Adjusted EBITDA $1.2M, down from $3.2M; Ultramist system sales fell to 82 units from 116.
Ultramist applicator revenue rose 13% to $7.3M, driven by 27% YoY unit volume growth.
Withdraws FY2026 guidance due to CMS proposed 2027 97610 reimbursement rule; will reassess after final rule.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.